Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANEB NASDAQ:EQ NASDAQ:OBSV NASDAQ:PHAS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$2.47-1.2%$2.41$0.80▼$3.42$101.47M-0.89164,389 shs33,079 shsEQEquillium$1.50-2.0%$1.09$0.27▼$2.35$89.25M1.583.34 million shs897,585 shsOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shs6,003 shsPHASPhaseBio Pharmaceuticals$0.00$0.07▼$4.08$3.50M2.57848,888 shs9.65 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals+0.40%+21.36%-3.10%+61.29%+10.13%EQEquillium-6.13%-16.85%+14.18%+374.42%+78.95%OBSVObsEva0.00%0.00%0.00%-75.00%-75.00%PHASPhaseBio Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$2.47-1.2%$2.41$0.80▼$3.42$101.47M-0.89164,389 shs33,079 shsEQEquillium$1.50-2.0%$1.09$0.27▼$2.35$89.25M1.583.34 million shs897,585 shsOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shs6,003 shsPHASPhaseBio Pharmaceuticals$0.00$0.07▼$4.08$3.50M2.57848,888 shs9.65 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals+0.40%+21.36%-3.10%+61.29%+10.13%EQEquillium-6.13%-16.85%+14.18%+374.42%+78.95%OBSVObsEva0.00%0.00%0.00%-75.00%-75.00%PHASPhaseBio Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANEBAnebulo Pharmaceuticals 2.50Moderate Buy$5.50122.67% UpsideEQEquillium 2.00Hold$1.00-33.33% DownsideOBSVObsEva 0.00N/AN/AN/APHASPhaseBio Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PHAS, ANEB, EQ, and OBSV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2025ANEBAnebulo PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 9/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANEBAnebulo PharmaceuticalsN/AN/AN/AN/A$0.15 per shareN/AEQEquillium$41.10M2.17N/AN/A$0.54 per share2.78OBSVObsEvaN/AN/AN/AN/A$0.41 per shareN/APHASPhaseBio Pharmaceuticals$818K0.00N/AN/A($1.93) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANEBAnebulo Pharmaceuticals-$8.20M-$0.26N/A∞N/AN/A-90.11%-84.53%9/24/2025 (Estimated)EQEquillium-$8.07M-$0.56N/AN/AN/A-19.62%-139.56%-90.56%11/12/2025 (Estimated)OBSVObsEva-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/APHASPhaseBio Pharmaceuticals-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/ALatest PHAS, ANEB, EQ, and OBSV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/24/2025Q4 2025ANEBAnebulo Pharmaceuticals-$0.05N/AN/AN/AN/AN/A8/14/2025Q2 2025EQEquillium-$0.14-$0.16-$0.02-$0.16N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANEBAnebulo PharmaceuticalsN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANEBAnebulo PharmaceuticalsN/A25.2925.29EQEquilliumN/A1.651.65OBSVObsEvaN/A0.610.61PHASPhaseBio PharmaceuticalsN/A0.470.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANEBAnebulo Pharmaceuticals28.40%EQEquillium27.05%OBSVObsEva17.52%PHASPhaseBio Pharmaceuticals49.02%Insider OwnershipCompanyInsider OwnershipANEBAnebulo Pharmaceuticals80.60%EQEquillium31.60%OBSVObsEva14.40%PHASPhaseBio Pharmaceuticals9.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANEBAnebulo Pharmaceuticals441.08 million7.97 millionNot OptionableEQEquillium4059.50 million40.70 millionNot OptionableOBSVObsEva5077.97 million66.74 millionNot OptionablePHASPhaseBio Pharmaceuticals6049.86 million44.92 millionNot OptionablePHAS, ANEB, EQ, and OBSV HeadlinesRecent News About These CompaniesPhio Pharma announces strategic initiative to create awareness of the comprehensive INTASYL siRNA portfolioJune 9, 2025 | pharmabiz.comPTicagrelor antidote safely, effectively restores platelet function and treats bleedingApril 1, 2025 | msn.comMedPharm appoints Bill Humphries as new CEOFebruary 6, 2025 | msn.comMedpharm Appoints Chief Executive OfficerFebruary 4, 2025 | contractpharma.comCPhaseBio Pharmaceuticals Inc.October 19, 2024 | thestreet.comPhiladelphia-area life sciences industry nears 900 layoffs since 2022October 11, 2024 | bizjournals.comPhaseBio Pharmaceuticals, Inc. (PHASQ)August 3, 2024 | ca.finance.yahoo.comModified Release Neurology Therapeutics Report 202…February 19, 2024 | pharmiweb.comPVelia Therapeutics Appoints Michael York as Chief Business OfficerDecember 14, 2023 | finance.yahoo.comLeading innovators in GLP-1 analogues for the pharmaceutical industryNovember 6, 2023 | pharmaceutical-technology.comPAlcami Announces CEO TransitionJune 5, 2023 | finance.yahoo.com8-K: PhaseBio Pharmaceuticals IncMay 12, 2023 | marketwatch.comAbsci Corporation: Absci Reports Fourth Quarter and Full Year 2022 Financial and Operating ResultsMarch 31, 2023 | finanznachrichten.deBioCryst Pharmaceuticals, Inc.: BioCryst Appoints Dr. Nancy Hutson as Chair of the BoardMarch 31, 2023 | finanznachrichten.deBioCryst Appoints Dr. Nancy Hutson as Chair of the BoardMarch 31, 2023 | finance.yahoo.comCardiomyopathy Medication Market Size and Forecast till 2031March 22, 2023 | marketwatch.comCardiomyopathy Medication Market Emerging Demand and Drive Growth by 2028 with Top Countries DataFebruary 28, 2023 | marketwatch.comJi Xing obtains global rights to cardiovascular candidate from PhasebioFebruary 9, 2023 | bioworld.comBBankrupt PhaseBio settles with investor-partner, handing off late-stage drugJanuary 18, 2023 | endpts.comESFJ Pharmaceuticals Announces Closing of Transfer of Bentracimab Assets from PhaseBio PharmaceuticalsJanuary 17, 2023 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines2 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025Can Identity Security Fuel CrowdStrike’s Next Growth Phase?By Chris Markoch | August 22, 2025Intel's New Buyers Mean Good News for Taiwan Semiconductor StockBy Gabriel Osorio-Mazilli | August 22, 2025Equal Weight ETFs: Hidden Upside in Today’s MarketBy Gabriel Osorio-Mazilli | August 23, 2025A Bull Case for Quantum Computing Stock Is Still AliveBy Gabriel Osorio-Mazilli | September 3, 2025PHAS, ANEB, EQ, and OBSV Company DescriptionsAnebulo Pharmaceuticals NASDAQ:ANEB$2.47 -0.03 (-1.20%) Closing price 04:00 PM EasternExtended Trading$2.45 -0.02 (-0.81%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.Equillium NASDAQ:EQ$1.50 -0.03 (-1.96%) Closing price 04:00 PM EasternExtended Trading$1.56 +0.05 (+3.67%) As of 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.ObsEva NASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.PhaseBio Pharmaceuticals NASDAQ:PHASPhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Bloom Energy Booms on AI Power Demand and Analyst Upgrades Can Apple’s iPhone 17 and AI Push Its Stock to New Highs? New Catalysts Build Positive Pressure on Intel Stock Oracle to Hit $1 Trillion Valuation in 2025: Here’s Why General Mills Is a Generational Opportunity for Income Investors Nike’s Red-Hot Analyst Buzz: Is a Comeback Brewing? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
